Nathaniel S. Gardiner is CLO & VP at ENANTA PHARMACEUTICALS INC (ENTA). They have made 5 open-market trades across 1 company since 2015, most recently 2024-02-26.
CIK 0001607643
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
2 open-market purchases totalling $59K since 2015, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ENTA | 75,688 | $841K |
Shares reported on the most recent Form 4, priced at the 2024-02-27 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ENTA | SELL | 2023-12-05 | 2023-12-06 | $9.63 | $23K | -5.6% | +27.9% | +59.0% |
| ENTA | SELL | 2019-02-13 | 2019-02-13 | $95.28 | $623K | +6.9% | +5.9% | -8.7% |
| ENTA | SELL | 2019-02-13 | 2019-02-13 | $95.28 | $312K | +6.9% | +5.9% | -8.7% |
| ENTA | BUY | 2016-05-11 | 2016-05-12 | $24.45 | $12K | +0.4% | -4.6% | -4.1% |
| ENTA | BUY | 2015-02-13 | 2015-02-17 | $33.23 | $47K | -17.8% | +5.4% | +5.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.